Evidence map›Paper›PMID 35107371›Full record

ArticleJournal of virology2022

Contribution of Neuraminidase to the Efficacy of Seasonal Split Influenza Vaccines in the Ferret Model.

Miruna E Rosu, Adinda Kok, Theo M Bestebroer, Dennis de Meulder, Elwin P Verveer, Mark R Pronk, Lennard J M Dekker, Theo M Luider, Mathilde Richard, Judith M A van den Brand and 2 more

Open access · hybridAbstract read
In one paragraph

Article in Journal of virology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
3.1field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 21 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Miruna E RosuDepartment of Viroscience, Erasmus Medical Centre, Rotterdam, the Netherlands.
Adinda KokDepartment of Viroscience, Erasmus Medical Centre, Rotterdam, the Netherlands.
Theo M BestebroerDepartment of Viroscience, Erasmus Medical Centre, Rotterdam, the Netherlands.
Dennis de MeulderDepartment of Viroscience, Erasmus Medical Centre, Rotterdam, the Netherlands.
Elwin P VerveerDepartment of Viroscience, Erasmus Medical Centre, Rotterdam, the Netherlands.
Mark R PronkDepartment of Viroscience, Erasmus Medical Centre, Rotterdam, the Netherlands.
Lennard J M DekkerDepartment of Neurology, Erasmus Medical Centre, Rotterdam, the Netherlands.
Theo M LuiderDepartment of Neurology, Erasmus Medical Centre, Rotterdam, the Netherlands.
Mathilde RichardDepartment of Viroscience, Erasmus Medical Centre, Rotterdam, the Netherlands.ORCID 0000-0003-0240-9312
Judith M A van den BrandDivision of Pathology, Faculty of Veterinary Medicine, Utrecht Universitygrid.5477.1, Utrecht, the Netherlands.
Ron A M FouchierDepartment of Viroscience, Erasmus Medical Centre, Rotterdam, the Netherlands.
Sander HerfstDepartment of Viroscience, Erasmus Medical Centre, Rotterdam, the Netherlands.ORCID 0000-0001-9866-8903
Erasmus University Rotterdam · NLUtrecht University · NL

Funding

HHS | Biomedical Advanced Research and Development Authority (BARDA) HHSO100201500033CNIAID NIH HHS HHSN272201400008C
6 · The paper itself

Abstract

Seasonal influenza vaccination takes into account primarily hemagglutinin (HA)-specific neutralizing antibody responses. However, the accumulation of substitutions in the antigenic regions of HA (i.e., antigenic drift) occasionally results in a mismatch between the vaccine and circulating strains. To prevent poor vaccine performance, we investigated whether an antigenically matched neuraminidase (NA) may compensate for reduced vaccine efficacy due to a mismatched HA. Ferrets were vaccinated twice with adjuvanted split inactivated influenza vaccines containing homologous HA and NA (vacH3N2), only homologous HA (vacH3N1), only homologous NA (vacH1N2), heterologous HA and NA (vacH1N1), or phosphate-buffered saline (vacPBS), followed by challenge with H3N2 virus (A/Netherlands/16190/1968). Ferrets vaccinated with homologous HA (vacH3N2 and vacH3N1) displayed minimum fever and weight loss compared to vacH1N1 and vacPBS ferrets, while ferrets vaccinated with NA-matched vacH1N2 displayed intermediate fever and weight loss. Vaccination with vacH1N2 further led to a reduction in virus shedding from the nose and undetectable virus titers in the lower respiratory tract, similarly to when the homologous vacH3N2 was used. Some protection was observed upon vacH1N1 vaccination, but this was not comparable to that observed for vacH1N2, again highlighting the important role of NA in vaccine-induced protection. These results illustrate that NA antibodies can prevent severe disease caused by influenza virus infection and that an antigenically matched NA in seasonal vaccines might prevent lower respiratory tract complications. This underlines the importance of considering NA during the yearly vaccine strain selection process, which may be particularly beneficial in seasons when the HA component of the vaccine is mismatched.

Indexed as

Influenza A virusInfluenza VaccinesNeuraminidaseOrthomyxoviridae InfectionsAnimalsAntibodies, ViralDisease Models, AnimalFerretsHemagglutininsInfluenza A Virus, H3N2 SubtypeSeasonsVaccines, InactivatedAntibodies, ViralHemagglutininsInfluenza VaccinesNeuraminidaseVaccines, Inactivatedferretinactivated vaccinesinfluenza virusneuraminidaseNI antibodies

Identifiers

PMID35107371
PMCPMC8941921
OpenAlexW4210667110

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.